Rhythm Pharmaceuticals (RYTM) Tops Q2 EPS by 8c

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q2 EPS of ($0.73), $0.08 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $71.26 million versus the consensus estimate of $67.53 million.

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.

You May Also Be Interested In

• Samsara Inc (IOT) call put ratio 4.5 calls to 1 put with a focus on September 4 weekly calls into quarter results
• Climb Bio (CLYM) PT Raised to $25 at Baird
• Victoria's Secret & Co. (VSXY) Tops Q2 EPS by 20c ; Offers Guidance